 Kathryn Colborn
Concepts (397)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 9 | 2022 | 821 | 3.030 |
Why?
| | Postoperative Complications | 26 | 2023 | 2322 | 2.410 |
Why?
| | Urinary Tract Infections | 3 | 2022 | 140 | 1.470 |
Why?
| | Surgical Procedures, Operative | 5 | 2023 | 230 | 1.390 |
Why?
| | Quality Improvement | 13 | 2023 | 996 | 1.350 |
Why?
| | Machine Learning | 6 | 2022 | 344 | 1.260 |
Why?
| | Malaria | 4 | 2023 | 61 | 1.220 |
Why?
| | Models, Statistical | 4 | 2020 | 676 | 0.870 |
Why?
| | Malaria, Falciparum | 2 | 2018 | 31 | 0.860 |
Why?
| | Sepsis | 5 | 2022 | 493 | 0.860 |
Why?
| | Postoperative Hemorrhage | 1 | 2022 | 84 | 0.840 |
Why?
| | Artificial Intelligence | 1 | 2023 | 147 | 0.830 |
Why?
| | Surgical Wound Infection | 4 | 2022 | 253 | 0.820 |
Why?
| | Malaria, Vivax | 2 | 2018 | 6 | 0.780 |
Why?
| | Plasmodium vivax | 2 | 2018 | 7 | 0.780 |
Why?
| | Retrospective Studies | 36 | 2023 | 13063 | 0.720 |
Why?
| | Inpatients | 4 | 2023 | 390 | 0.690 |
Why?
| | Humans | 101 | 2023 | 121869 | 0.690 |
Why?
| | Pancreatic Neoplasms | 5 | 2023 | 771 | 0.670 |
Why?
| | Poisson Distribution | 1 | 2018 | 74 | 0.640 |
Why?
| | Plasmodium falciparum | 1 | 2018 | 35 | 0.640 |
Why?
| | Health Plan Implementation | 1 | 2019 | 128 | 0.640 |
Why?
| | Databases, Factual | 12 | 2023 | 1285 | 0.610 |
Why?
| | Hospitalization | 6 | 2021 | 1873 | 0.610 |
Why?
| | Risk Assessment | 15 | 2023 | 3248 | 0.610 |
Why?
| | Mosquito Control | 2 | 2023 | 27 | 0.590 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2023 | 222 | 0.560 |
Why?
| | Palliative Care | 6 | 2023 | 613 | 0.550 |
Why?
| | Mosquito Nets | 1 | 2015 | 2 | 0.550 |
Why?
| | Anopheles | 1 | 2015 | 17 | 0.540 |
Why?
| | Shock, Septic | 3 | 2022 | 192 | 0.530 |
Why?
| | Surgeons | 3 | 2023 | 227 | 0.520 |
Why?
| | Drug Prescriptions | 3 | 2021 | 270 | 0.500 |
Why?
| | Middle Aged | 29 | 2023 | 28961 | 0.470 |
Why?
| | Ambulatory Surgical Procedures | 2 | 2023 | 52 | 0.450 |
Why?
| | Risk Factors | 21 | 2023 | 9419 | 0.450 |
Why?
| | Patient Discharge | 2 | 2020 | 843 | 0.450 |
Why?
| | Hospital Mortality | 1 | 2016 | 878 | 0.430 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2023 | 64 | 0.430 |
Why?
| | Thoracic Surgery | 2 | 2023 | 141 | 0.420 |
Why?
| | Adult | 28 | 2023 | 32683 | 0.420 |
Why?
| | Primary Health Care | 2 | 2019 | 1619 | 0.410 |
Why?
| | Algorithms | 4 | 2019 | 1618 | 0.400 |
Why?
| | Female | 41 | 2023 | 63903 | 0.400 |
Why?
| | Aged | 21 | 2023 | 20705 | 0.400 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 405 | 0.400 |
Why?
| | Influenza, Human | 3 | 2021 | 556 | 0.380 |
Why?
| | Breast Neoplasms | 4 | 2023 | 1970 | 0.380 |
Why?
| | Male | 37 | 2023 | 60475 | 0.370 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2023 | 238 | 0.370 |
Why?
| | Emergency Treatment | 2 | 2021 | 113 | 0.360 |
Why?
| | Child, Preschool | 13 | 2023 | 9776 | 0.360 |
Why?
| | Neoadjuvant Therapy | 5 | 2023 | 336 | 0.340 |
Why?
| | Hospitals | 3 | 2022 | 598 | 0.320 |
Why?
| | Research Design | 3 | 2022 | 1003 | 0.320 |
Why?
| | Osteoarthritis, Knee | 2 | 2021 | 228 | 0.320 |
Why?
| | Autism Spectrum Disorder | 2 | 2023 | 342 | 0.310 |
Why?
| | Incidence | 6 | 2020 | 2520 | 0.310 |
Why?
| | Arthroplasty, Replacement, Knee | 2 | 2021 | 248 | 0.300 |
Why?
| | Rectal Neoplasms | 2 | 2019 | 120 | 0.300 |
Why?
| | Chagas Disease | 2 | 2018 | 33 | 0.300 |
Why?
| | Mass Drug Administration | 3 | 2023 | 7 | 0.300 |
Why?
| | Quality of Life | 7 | 2023 | 2453 | 0.300 |
Why?
| | Aged, 80 and over | 9 | 2023 | 6974 | 0.290 |
Why?
| | Cohort Studies | 10 | 2023 | 5300 | 0.290 |
Why?
| | Colorado | 7 | 2021 | 4344 | 0.280 |
Why?
| | Patient Reported Outcome Measures | 3 | 2022 | 244 | 0.280 |
Why?
| | Asthma | 1 | 2019 | 2130 | 0.270 |
Why?
| | United States | 15 | 2023 | 13209 | 0.260 |
Why?
| | Emergency Service, Hospital | 3 | 2020 | 1841 | 0.260 |
Why?
| | Heart Failure | 4 | 2018 | 2142 | 0.250 |
Why?
| | Analgesics, Opioid | 3 | 2021 | 781 | 0.240 |
Why?
| | Metastasectomy | 1 | 2023 | 11 | 0.240 |
Why?
| | Hernia, Hiatal | 1 | 2023 | 34 | 0.240 |
Why?
| | Young Adult | 11 | 2020 | 11223 | 0.240 |
Why?
| | Specialties, Surgical | 2 | 2021 | 72 | 0.230 |
Why?
| | Endarterectomy, Carotid | 1 | 2023 | 47 | 0.230 |
Why?
| | Predictive Value of Tests | 4 | 2022 | 1965 | 0.230 |
Why?
| | Thoracic Surgical Procedures | 1 | 2023 | 63 | 0.230 |
Why?
| | Insecticides | 1 | 2023 | 39 | 0.230 |
Why?
| | Practice Patterns, Physicians' | 3 | 2021 | 1247 | 0.220 |
Why?
| | Carotid Stenosis | 1 | 2023 | 77 | 0.220 |
Why?
| | MEF2 Transcription Factors | 1 | 2022 | 59 | 0.220 |
Why?
| | Microcephaly | 1 | 2023 | 58 | 0.220 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2023 | 61 | 0.220 |
Why?
| | Risk Adjustment | 1 | 2023 | 84 | 0.220 |
Why?
| | Ischemic Attack, Transient | 1 | 2023 | 65 | 0.220 |
Why?
| | Polypharmacy | 1 | 2023 | 76 | 0.220 |
Why?
| | Pain, Postoperative | 2 | 2021 | 212 | 0.220 |
Why?
| | Sentinel Lymph Node | 1 | 2022 | 40 | 0.220 |
Why?
| | Adolescent | 13 | 2023 | 19126 | 0.220 |
Why?
| | Neuroendocrine Tumors | 1 | 2023 | 82 | 0.220 |
Why?
| | Medication Therapy Management | 1 | 2023 | 76 | 0.220 |
Why?
| | Delirium | 1 | 2023 | 69 | 0.220 |
Why?
| | Drug Hypersensitivity | 1 | 2023 | 83 | 0.210 |
Why?
| | Galectins | 1 | 2022 | 22 | 0.210 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2019 | 42 | 0.210 |
Why?
| | Mozambique | 2 | 2018 | 5 | 0.210 |
Why?
| | Ivermectin | 1 | 2021 | 11 | 0.210 |
Why?
| | Preoperative Care | 2 | 2021 | 344 | 0.200 |
Why?
| | Mastectomy, Segmental | 1 | 2021 | 90 | 0.200 |
Why?
| | Knee Joint | 2 | 2021 | 361 | 0.200 |
Why?
| | Intensive Care Units | 2 | 2022 | 618 | 0.200 |
Why?
| | Dysbiosis | 1 | 2022 | 147 | 0.200 |
Why?
| | Prognosis | 7 | 2023 | 3603 | 0.200 |
Why?
| | Gastric Bypass | 1 | 2022 | 93 | 0.200 |
Why?
| | Terminal Care | 1 | 2023 | 181 | 0.200 |
Why?
| | Oxycodone | 1 | 2021 | 47 | 0.200 |
Why?
| | New Guinea | 2 | 2018 | 4 | 0.200 |
Why?
| | Program Evaluation | 3 | 2021 | 876 | 0.200 |
Why?
| | Surgery Department, Hospital | 1 | 2020 | 23 | 0.190 |
Why?
| | Arthroplasty | 1 | 2020 | 52 | 0.190 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 44 | 0.190 |
Why?
| | Faculty | 1 | 2021 | 132 | 0.190 |
Why?
| | Artemisinins | 1 | 2019 | 2 | 0.180 |
Why?
| | Infant | 8 | 2023 | 8440 | 0.180 |
Why?
| | Antimalarials | 1 | 2019 | 24 | 0.180 |
Why?
| | Hypersensitivity | 1 | 2023 | 254 | 0.180 |
Why?
| | Prisons | 1 | 2010 | 56 | 0.180 |
Why?
| | Zebrafish Proteins | 1 | 2022 | 283 | 0.180 |
Why?
| | Venous Thromboembolism | 1 | 2023 | 235 | 0.180 |
Why?
| | Waiting Lists | 2 | 2021 | 226 | 0.180 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2019 | 127 | 0.180 |
Why?
| | Organ Transplantation | 1 | 2021 | 164 | 0.180 |
Why?
| | Latent Tuberculosis | 1 | 2010 | 65 | 0.180 |
Why?
| | Rural Population | 2 | 2020 | 486 | 0.180 |
Why?
| | General Surgery | 1 | 2021 | 149 | 0.180 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 58 | 0.170 |
Why?
| | Obesity, Morbid | 1 | 2022 | 202 | 0.170 |
Why?
| | Laparoscopy | 1 | 2023 | 421 | 0.170 |
Why?
| | Anti-Infective Agents | 1 | 2022 | 247 | 0.170 |
Why?
| | Outpatients | 1 | 2022 | 335 | 0.170 |
Why?
| | Treatment Outcome | 9 | 2023 | 9654 | 0.170 |
Why?
| | Burns | 1 | 2022 | 249 | 0.170 |
Why?
| | Aftercare | 1 | 2020 | 196 | 0.170 |
Why?
| | Condoms, Female | 1 | 2008 | 6 | 0.170 |
Why?
| | Quinolines | 1 | 2019 | 130 | 0.170 |
Why?
| | Reproductive Medicine | 1 | 2008 | 13 | 0.170 |
Why?
| | Triage | 1 | 2021 | 208 | 0.170 |
Why?
| | Social Marketing | 1 | 2008 | 14 | 0.170 |
Why?
| | Soft Tissue Infections | 1 | 2008 | 31 | 0.170 |
Why?
| | Datasets as Topic | 1 | 2019 | 109 | 0.170 |
Why?
| | Autistic Disorder | 1 | 2020 | 167 | 0.170 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 198 | 0.170 |
Why?
| | Cardiac Surgical Procedures | 1 | 2023 | 494 | 0.170 |
Why?
| | Ventricular Function | 1 | 2018 | 63 | 0.170 |
Why?
| | Community Participation | 1 | 2019 | 126 | 0.170 |
Why?
| | Cognition | 2 | 2023 | 1083 | 0.170 |
Why?
| | Hospitals, University | 1 | 2018 | 183 | 0.170 |
Why?
| | Developed Countries | 1 | 2018 | 36 | 0.170 |
Why?
| | Herpesvirus 4, Human | 1 | 2019 | 136 | 0.160 |
Why?
| | Zebrafish | 1 | 2022 | 469 | 0.160 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2019 | 73 | 0.160 |
Why?
| | Computers, Handheld | 1 | 2018 | 25 | 0.160 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 403 | 0.160 |
Why?
| | Patient Admission | 1 | 2019 | 189 | 0.160 |
Why?
| | Population Groups | 1 | 2018 | 56 | 0.160 |
Why?
| | ROC Curve | 1 | 2019 | 496 | 0.160 |
Why?
| | Climate | 1 | 2018 | 95 | 0.160 |
Why?
| | Immunoglobulin A | 1 | 2019 | 176 | 0.160 |
Why?
| | Sentinel Surveillance | 1 | 2017 | 40 | 0.160 |
Why?
| | Geography | 1 | 2018 | 196 | 0.160 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2023 | 119 | 0.160 |
Why?
| | Occupational Health | 1 | 2010 | 189 | 0.160 |
Why?
| | Safety-net Providers | 1 | 2019 | 110 | 0.160 |
Why?
| | Substance Abuse, Intravenous | 1 | 2008 | 94 | 0.160 |
Why?
| | Recovery of Function | 1 | 2021 | 612 | 0.160 |
Why?
| | Condoms | 1 | 2008 | 125 | 0.150 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 309 | 0.150 |
Why?
| | Child | 10 | 2023 | 19282 | 0.150 |
Why?
| | Patient Compliance | 1 | 2021 | 569 | 0.150 |
Why?
| | Epidemics | 1 | 2018 | 76 | 0.150 |
Why?
| | Lymph Node Excision | 3 | 2023 | 159 | 0.150 |
Why?
| | Defibrillators, Implantable | 1 | 2022 | 411 | 0.150 |
Why?
| | Gastroenteritis | 1 | 2017 | 64 | 0.150 |
Why?
| | Anxiety Disorders | 1 | 2010 | 319 | 0.150 |
Why?
| | Occupational Exposure | 1 | 2010 | 309 | 0.150 |
Why?
| | Membrane Glycoproteins | 1 | 2019 | 450 | 0.150 |
Why?
| | Cell Phone | 1 | 2017 | 83 | 0.150 |
Why?
| | Students, Medical | 1 | 2021 | 320 | 0.150 |
Why?
| | Influenza Vaccines | 1 | 2021 | 496 | 0.150 |
Why?
| | Radiotherapy, Conformal | 1 | 2016 | 67 | 0.150 |
Why?
| | Nurse Practitioners | 1 | 2018 | 109 | 0.150 |
Why?
| | Adenocarcinoma | 1 | 2023 | 833 | 0.140 |
Why?
| | Logistic Models | 4 | 2023 | 2037 | 0.140 |
Why?
| | Fever | 1 | 2017 | 291 | 0.140 |
Why?
| | Mass Screening | 2 | 2020 | 1089 | 0.140 |
Why?
| | Alcoholism | 1 | 2023 | 808 | 0.140 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2017 | 114 | 0.140 |
Why?
| | Patient Readmission | 2 | 2020 | 678 | 0.140 |
Why?
| | Cannabidiol | 1 | 2016 | 57 | 0.140 |
Why?
| | Melanoma | 1 | 2022 | 705 | 0.140 |
Why?
| | Morbidity | 3 | 2022 | 300 | 0.140 |
Why?
| | Healthcare Disparities | 2 | 2018 | 492 | 0.140 |
Why?
| | Forecasting | 1 | 2018 | 382 | 0.140 |
Why?
| | Models, Organizational | 1 | 2016 | 148 | 0.140 |
Why?
| | Humidity | 1 | 2015 | 45 | 0.130 |
Why?
| | Antibodies, Viral | 1 | 2019 | 579 | 0.130 |
Why?
| | Advance Care Planning | 1 | 2018 | 189 | 0.130 |
Why?
| | Mobile Applications | 1 | 2017 | 156 | 0.130 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2023 | 764 | 0.130 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 403 | 0.130 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1438 | 0.130 |
Why?
| | Skin Neoplasms | 1 | 2022 | 837 | 0.130 |
Why?
| | Anticonvulsants | 1 | 2016 | 192 | 0.130 |
Why?
| | Diarrhea | 3 | 2023 | 180 | 0.130 |
Why?
| | Massage | 2 | 2010 | 46 | 0.130 |
Why?
| | Emergency Medical Services | 1 | 2021 | 553 | 0.130 |
Why?
| | Stroke | 1 | 2023 | 1067 | 0.130 |
Why?
| | Pain | 1 | 2010 | 745 | 0.130 |
Why?
| | Chronic Pain | 1 | 2018 | 212 | 0.120 |
Why?
| | Parasitemia | 1 | 2013 | 9 | 0.120 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1871 | 0.120 |
Why?
| | Environmental Exposure | 1 | 2018 | 427 | 0.120 |
Why?
| | Family Practice | 1 | 2018 | 486 | 0.120 |
Why?
| | Heart Defects, Congenital | 1 | 2020 | 714 | 0.120 |
Why?
| | Indians, North American | 1 | 2009 | 599 | 0.120 |
Why?
| | Models, Biological | 1 | 2021 | 1772 | 0.120 |
Why?
| | Software | 1 | 2018 | 653 | 0.120 |
Why?
| | Research | 1 | 2016 | 446 | 0.110 |
Why?
| | Medicaid | 1 | 2017 | 409 | 0.110 |
Why?
| | Epilepsy | 1 | 2016 | 287 | 0.110 |
Why?
| | Myocardial Infarction | 1 | 2020 | 1142 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2023 | 1254 | 0.110 |
Why?
| | Multicenter Studies as Topic | 2 | 2023 | 244 | 0.110 |
Why?
| | Heart-Assist Devices | 1 | 2018 | 486 | 0.110 |
Why?
| | Temperature | 1 | 2015 | 641 | 0.110 |
Why?
| | Axilla | 2 | 2023 | 60 | 0.110 |
Why?
| | Feedback | 2 | 2023 | 159 | 0.110 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2023 | 363 | 0.110 |
Why?
| | Pain Management | 2 | 2010 | 303 | 0.110 |
Why?
| | Mastectomy | 2 | 2023 | 126 | 0.110 |
Why?
| | Prevalence | 3 | 2023 | 2444 | 0.110 |
Why?
| | Uganda | 2 | 2023 | 92 | 0.100 |
Why?
| | Disease Progression | 1 | 2019 | 2582 | 0.100 |
Why?
| | Age Factors | 4 | 2021 | 3173 | 0.100 |
Why?
| | Lymphatic Metastasis | 2 | 2023 | 312 | 0.100 |
Why?
| | Heart Transplantation | 1 | 2017 | 759 | 0.100 |
Why?
| | Internship and Residency | 1 | 2021 | 1045 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2876 | 0.100 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2237 | 0.090 |
Why?
| | Postoperative Period | 2 | 2021 | 323 | 0.090 |
Why?
| | Anti-HIV Agents | 1 | 2016 | 675 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 2017 | 0.090 |
Why?
| | Laboratories | 2 | 2021 | 106 | 0.090 |
Why?
| | Pandemics | 3 | 2023 | 1316 | 0.090 |
Why?
| | Guatemala | 2 | 2023 | 299 | 0.090 |
Why?
| | Prospective Studies | 4 | 2022 | 6629 | 0.090 |
Why?
| | Lymph Nodes | 2 | 2023 | 468 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2016 | 855 | 0.090 |
Why?
| | Feeding Behavior | 1 | 2015 | 625 | 0.090 |
Why?
| | Seasons | 2 | 2020 | 469 | 0.090 |
Why?
| | Survival Rate | 2 | 2023 | 1828 | 0.080 |
Why?
| | Immunization Programs | 1 | 2009 | 203 | 0.080 |
Why?
| | Referral and Consultation | 2 | 2023 | 680 | 0.080 |
Why?
| | Comorbidity | 2 | 2022 | 1633 | 0.080 |
Why?
| | Length of Stay | 2 | 2023 | 1056 | 0.080 |
Why?
| | Urban Population | 2 | 2020 | 433 | 0.070 |
Why?
| | Follow-Up Studies | 3 | 2021 | 4883 | 0.070 |
Why?
| | School Health Services | 1 | 2009 | 205 | 0.070 |
Why?
| | Affect | 1 | 2008 | 264 | 0.070 |
Why?
| | Insurance Coverage | 2 | 2017 | 217 | 0.070 |
Why?
| | Patient Satisfaction | 2 | 2021 | 618 | 0.070 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 4713 | 0.070 |
Why?
| | Body Mass Index | 2 | 2023 | 2174 | 0.060 |
Why?
| | Pneumonia | 2 | 2020 | 597 | 0.060 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1180 | 0.060 |
Why?
| | Cytokines | 2 | 2023 | 1904 | 0.060 |
Why?
| | Acute Disease | 2 | 2017 | 986 | 0.060 |
Why?
| | Surveys and Questionnaires | 3 | 2021 | 4922 | 0.060 |
Why?
| | Health Care Surveys | 2 | 2010 | 564 | 0.060 |
Why?
| | Community Health Workers | 1 | 2023 | 49 | 0.060 |
Why?
| | Herniorrhaphy | 1 | 2023 | 50 | 0.060 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 12 | 0.060 |
Why?
| | Health Facilities | 1 | 2023 | 75 | 0.060 |
Why?
| | Growth Disorders | 1 | 2023 | 83 | 0.060 |
Why?
| | Death | 1 | 2023 | 114 | 0.060 |
Why?
| | Anti-Bacterial Agents | 2 | 2023 | 1491 | 0.060 |
Why?
| | Biological Variation, Population | 1 | 2022 | 25 | 0.060 |
Why?
| | Body Surface Area | 1 | 2022 | 27 | 0.060 |
Why?
| | Cough | 1 | 2023 | 108 | 0.060 |
Why?
| | Burn Units | 1 | 2022 | 26 | 0.060 |
Why?
| | Papua New Guinea | 1 | 2012 | 7 | 0.060 |
Why?
| | Vomiting | 1 | 2023 | 131 | 0.060 |
Why?
| | Breast | 1 | 2023 | 144 | 0.060 |
Why?
| | Patient Acuity | 1 | 2022 | 38 | 0.050 |
Why?
| | HIV Infections | 1 | 2016 | 2506 | 0.050 |
Why?
| | Patients | 1 | 2023 | 138 | 0.050 |
Why?
| | Carotid Arteries | 1 | 2023 | 191 | 0.050 |
Why?
| | Neutrophil Infiltration | 1 | 2022 | 101 | 0.050 |
Why?
| | Focus Groups | 1 | 2023 | 382 | 0.050 |
Why?
| | Inappropriate Prescribing | 1 | 2022 | 48 | 0.050 |
Why?
| | Neurosurgical Procedures | 1 | 2023 | 165 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2023 | 678 | 0.050 |
Why?
| | Gastrectomy | 1 | 2022 | 84 | 0.050 |
Why?
| | Demography | 1 | 2022 | 286 | 0.050 |
Why?
| | Educational Status | 1 | 2023 | 445 | 0.050 |
Why?
| | Sample Size | 1 | 2021 | 133 | 0.050 |
Why?
| | Habits | 1 | 2020 | 42 | 0.050 |
Why?
| | Ligands | 1 | 2023 | 556 | 0.050 |
Why?
| | Preoperative Period | 1 | 2021 | 114 | 0.050 |
Why?
| | Chemoradiotherapy | 1 | 2022 | 201 | 0.050 |
Why?
| | Receptor, ErbB-2 | 1 | 2023 | 323 | 0.050 |
Why?
| | Censuses | 1 | 2020 | 21 | 0.050 |
Why?
| | Fear | 1 | 2023 | 311 | 0.050 |
Why?
| | Research Personnel | 1 | 2022 | 163 | 0.050 |
Why?
| | South Africa | 1 | 2021 | 160 | 0.050 |
Why?
| | Reoperation | 1 | 2023 | 578 | 0.050 |
Why?
| | Animals | 3 | 2022 | 34134 | 0.050 |
Why?
| | Policy | 1 | 2021 | 130 | 0.050 |
Why?
| | Schools, Medical | 1 | 2021 | 154 | 0.050 |
Why?
| | Emergencies | 1 | 2021 | 161 | 0.050 |
Why?
| | Blood Proteins | 1 | 2022 | 251 | 0.050 |
Why?
| | Elective Surgical Procedures | 1 | 2021 | 169 | 0.050 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2019 | 40 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2021 | 512 | 0.050 |
Why?
| | Mentors | 1 | 2021 | 164 | 0.050 |
Why?
| | Early Diagnosis | 1 | 2020 | 247 | 0.040 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 1 | 2019 | 9 | 0.040 |
Why?
| | Urination Disorders | 1 | 2019 | 15 | 0.040 |
Why?
| | Leucovorin | 1 | 2019 | 46 | 0.040 |
Why?
| | Organoplatinum Compounds | 1 | 2019 | 42 | 0.040 |
Why?
| | Societies, Medical | 1 | 2023 | 744 | 0.040 |
Why?
| | Program Development | 1 | 2021 | 371 | 0.040 |
Why?
| | Kenya | 1 | 2019 | 97 | 0.040 |
Why?
| | Survivors | 1 | 2022 | 418 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2023 | 1574 | 0.040 |
Why?
| | Risk | 1 | 2022 | 925 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 564 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2022 | 509 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 350 | 0.040 |
Why?
| | Cardiovascular Nursing | 1 | 2018 | 3 | 0.040 |
Why?
| | Drug Combinations | 1 | 2019 | 301 | 0.040 |
Why?
| | Washington | 1 | 2008 | 137 | 0.040 |
Why?
| | Fluorouracil | 1 | 2019 | 158 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 544 | 0.040 |
Why?
| | Colombia | 1 | 2018 | 43 | 0.040 |
Why?
| | Time Factors | 2 | 2021 | 6889 | 0.040 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2019 | 145 | 0.040 |
Why?
| | Range of Motion, Articular | 1 | 2020 | 374 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2010 | 272 | 0.040 |
Why?
| | Rectum | 1 | 2019 | 161 | 0.040 |
Why?
| | Hospitals, Veterans | 1 | 2009 | 253 | 0.040 |
Why?
| | Coinfection | 1 | 2019 | 124 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 884 | 0.040 |
Why?
| | Patient-Centered Care | 1 | 2023 | 509 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2019 | 5336 | 0.040 |
Why?
| | Mental Health | 1 | 2023 | 553 | 0.040 |
Why?
| | Mortality | 1 | 2019 | 325 | 0.040 |
Why?
| | Prisoners | 1 | 2008 | 93 | 0.040 |
Why?
| | Proctitis | 1 | 2016 | 4 | 0.040 |
Why?
| | Viral Load | 1 | 2019 | 432 | 0.040 |
Why?
| | Odds Ratio | 1 | 2010 | 1052 | 0.040 |
Why?
| | Urogenital System | 1 | 2016 | 12 | 0.040 |
Why?
| | Prosthesis Design | 1 | 2018 | 286 | 0.040 |
Why?
| | Latin America | 1 | 2016 | 75 | 0.040 |
Why?
| | Weight Loss | 1 | 2022 | 736 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2021 | 595 | 0.040 |
Why?
| | Anxiety | 1 | 2023 | 873 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 245 | 0.040 |
Why?
| | Population Surveillance | 1 | 2019 | 439 | 0.040 |
Why?
| | Medically Uninsured | 1 | 2017 | 132 | 0.040 |
Why?
| | Guideline Adherence | 1 | 2010 | 552 | 0.030 |
Why?
| | Radiation Injuries | 1 | 2016 | 138 | 0.030 |
Why?
| | Health Status | 1 | 2021 | 797 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2008 | 1190 | 0.030 |
Why?
| | Echocardiography | 1 | 2018 | 594 | 0.030 |
Why?
| | Self Care | 1 | 2018 | 361 | 0.030 |
Why?
| | Sexually Transmitted Diseases | 1 | 2008 | 228 | 0.030 |
Why?
| | Plant Extracts | 1 | 2016 | 168 | 0.030 |
Why?
| | Public Health | 1 | 2019 | 470 | 0.030 |
Why?
| | Hemorrhage | 1 | 2019 | 647 | 0.030 |
Why?
| | Curriculum | 1 | 2021 | 898 | 0.030 |
Why?
| | Insurance, Health | 1 | 2017 | 258 | 0.030 |
Why?
| | Electrocardiography | 1 | 2018 | 641 | 0.030 |
Why?
| | Neoplasms | 1 | 2008 | 2241 | 0.030 |
Why?
| | Administration, Oral | 1 | 2016 | 793 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 3078 | 0.030 |
Why?
| | Transcription Factors | 1 | 2022 | 1629 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 886 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 901 | 0.030 |
Why?
| | Vaccination | 1 | 2021 | 1218 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1472 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 2999 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2020 | 3314 | 0.030 |
Why?
| | Sex Factors | 1 | 2018 | 1898 | 0.030 |
Why?
| | Communication | 1 | 2018 | 755 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2010 | 1511 | 0.030 |
Why?
| | Health Promotion | 1 | 2008 | 711 | 0.030 |
Why?
| | Biomarkers | 1 | 2022 | 3652 | 0.030 |
Why?
| | Inflammation | 1 | 2022 | 2522 | 0.020 |
Why?
| | Lung | 1 | 2023 | 3767 | 0.020 |
Why?
| | Registries | 1 | 2018 | 1956 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 2802 | 0.020 |
Why?
| | Veterans | 1 | 2009 | 1148 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2008 | 275 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2009 | 816 | 0.010 |
Why?
|
|
Colborn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|